OR WAIT null SECS
October 14, 2025
Video
Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.
October 12, 2025
Article
An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.
October 09, 2025
The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.
October 07, 2025
The new therapy, marketed as Jascayd, previously demonstrated safety and efficacy in the phase 3 FIBRONEER-IPF trial.
July 20, 2025
Podcast
An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.
July 16, 2025
Endeavor BioMedicines' Taladegib gains orphan drug status for idiopathic pulmonary fibrosis, showing promise in improving lung function and patient outcomes.
Yale researchers developed an AI model that illuminates critical details about—and possible treatments for—idiopathic pulmonary fibrosis. It could do so for many other diseases.
June 06, 2025
Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.
May 26, 2025
In this interview, nerandomilast’s safety profile in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is highlighted.
May 25, 2025
This interview highlights phase 3 trial data on nerandomilast’s use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
